WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Wisconsin prison inmate pleads not guilty to killing cellmateTwo Premier League stars, both 19, arrested in a rape probe are 'suspended by their club'Crown Princess Victoria of Sweden is the image of glamour in a flowing white gownWhat to listen for during Supreme Court arguments on Donald Trump and presidential immunityMarried couple are charged with fraud after 'dineMicrosoft and Amazon face scrutiny from UK competition watchdog over recent AI dealsElection 2024: Puerto Rico Republicans award Trump all 23 delegatesDoctors combine a pig kidney transplant and a heart device in a bid to extend woman's lifeAttempt to expedite ethics probe of Minnesota state senator charged with burglary fails on tie votePascal Siakam leads resurgent Pacers offense in 125
2.888s , 6501.7578125 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,International Index news portal